Early promise for malaria vaccine

2013-08-09 08:07

Multimedia   ·   User Galleries   ·   News in Pictures Send us your pictures  ·  Send us your stories

Washington - A new kind of malaria vaccine that mimics the effects of mosquito bites has shown early promise by offering 100 percent protection to a dozen human volunteers, researchers said on Thursday.

Maryland-based Sanaria's PfSPZ vaccine contains live parasites and is complicated to make because it requires scientists to dissect the salivary glands of mosquitoes to get at the parasites that cause malaria.

These sporozoites are then weakened so they cannot cause illness and incorporated into a vaccine which must be injected into a person's veins several times, with each shot about a month apart.

A test of the same vaccine two years ago that administered it into the skin of patients, the way most vaccines are given, showed protection in only two of 44 volunteers.

But the latest trial showed that injecting the vaccine into the bloodstream protected against malaria in all six volunteers who received a five-shot regimen at the highest dosage, according to the results published in the US journal Science.

Six of nine volunteers in a separate group that received four shots of the highest dose - 135 000 sporozoites per injection - were also fully protected against malaria, it said.

The study included 57 people - including 40 who received the vaccine in varying doses and 17 controls.

Co-author Robert Seder at the National Institute of Allergy and Infectious Diseases told Science the findings are "very promising", but that the vaccine needs more study.

"We need to repeat it in a larger number of people."

Lead researcher Stephen Hoffman, the chief executive of Sanaria, is also teaming with Harvard University engineers to automate the process of dissecting the mosquitoes, Science reported.

The company currently employs "about 12 to 15 'dissectors' who can each tease apart about 150 mosquitoes an hour", it said.

Sanaria's PfSPZ Vaccine contains "live, weakened, purified malaria parasites that do not cause illness", said a company statement.

"While we're still in the early stages of testing, we believe this vaccine will be used to eliminate malaria," said Hoffman.

"It's reasonable to suggest that within three-to-five years, a safe, reliable vaccine could be a commercial reality and provide medical benefit to a huge population."

Next, a series of small clinical trials are planned for Tanzania, Germany and the United States.

Malaria infected about 220 million people in 2010 and killed 660 000 according to the World Health Organisation. Most of the deaths were among children in Africa.

Another vaccine effort under way is the RTS,S trial. Its phase III results, reported in Science in 2012, showed 31% effectiveness in young infants and 56% in older babies and toddlers.

Hoffman told Science he realised years ago that a single protein vaccine like RTS,S would "never do the job" of warding off malaria which is caused by a 5 000-gene parasite.

He was inspired instead by studies in the 1970s that showed 90% of volunteers were protected against malaria after getting more than 1 000 bites from infected mosquitoes that had undergone radiation to weaken the Plasmodium falciparum parasite.

"My colleagues and I are very excited about working with Sanaria," said a statement from Salim Abdullah, Chief Executive Director of Tanzania's Ifakara Health Institute.

"This great advance in the development of a whole parasite vaccine immediately opens up important opportunities for immunization studies in malaria endemic countries."

Science also quoted Pedro Alonso of the Barcelona Institute for Global Health in Spain, a leading researcher on the RTS,S vaccine, as saying the results were "extremely encouraging."

"This is a really important, really exciting proof of concept," he said.

Read more on:    who  |  us  |  insects  |  health  |  research

Join the conversation!

24.com encourages commentary submitted via MyNews24. Contributions of 200 words or more will be considered for publication.

We reserve editorial discretion to decide what will be published.
Read our comments policy for guidelines on contributions.

24.com publishes all comments posted on articles provided that they adhere to our Comments Policy. Should you wish to report a comment for editorial review, please do so by clicking the 'Report Comment' button to the right of each comment.

Comment on this story
Comments have been closed for this article.

Inside News24

Traffic Alerts
There are new stories on the homepage. Click here to see them.


Create Profile

Creating your profile will enable you to submit photos and stories to get published on News24.

Please provide a username for your profile page:

This username must be unique, cannot be edited and will be used in the URL to your profile page across the entire 24.com network.


Location Settings

News24 allows you to edit the display of certain components based on a location. If you wish to personalise the page based on your preferences, please select a location for each component and click "Submit" in order for the changes to take affect.

Facebook Sign-In

Hi News addict,

Join the News24 Community to be involved in breaking the news.

Log in with Facebook to comment and personalise news, weather and listings.